Grifols 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sobi 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

GSK 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tislelizumab, an antibody targeting PD-1.

NCT07551479 clinical trial report covering Oxaliplatin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07549412 clinical trial report covering Precemtabart tocentecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

CTR20261536 clinical trial report covering Ketoprofen, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07549399 clinical trial report covering Cetuximab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07551492 clinical trial report covering Ribupatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

CTR20261636 clinical trial report covering Interferon alpha-2b(Anhui Anke Biotechnology), Phase 3, endpoints, sponsor, geography, readout timing and developme

NCT07552389 clinical trial report covering HL-1113, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07553182 clinical trial report covering Filgotinib Maleate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.